Researchers at LA BioMed in Torrance, CA have been working to create a therapeutic vaccine for 2 years to fight infections caused by Candida auris.
Researchers at LA BioMed in Torrance, CA have been working to create a therapeutic vaccine for 2 years to fight infections caused by Candida auris. The lab studies have been most encouraging. With its resistance to anti-fungal drugs, a vaccine is likely the best way to combat the antibiotic-resistant nature of this emerging and deadly pathogen.
Drs. Ashraf Ibrahim and Jack Edwards, in conjunction with the LA BioMed spinoff company NovaDigm Therapeutics, are developing a vaccine specifically designed to combat these infections, largely hospital acquired, and very often fatal. Recent media coverage documents the necessity of exactly this type of non-antibiotic approach.
About LA BioMed
LA BioMed is an engine of innovation with a global reach and a 67-year reputation of improving and saving lives. Driven by the positive social impacts of breakthrough therapies, the Southern California-based research institute and incubator – with over 100 principal investigators (PhDs, MDs and MD/PhDs) working on over 600 research studies, including therapies for multiple orphan diseases – is an essential element to one of the nation’s top-ten biotech clusters. Find out more at https://labiomed.org.
